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Abstract Continuous subcutaneous insulin infusion
(CSII) is considered an option for type 1 diabetic patients
unsatisfactorily controlled with multiple daily injections
(MDI). Short-acting analogs are superior to regular human
insulin in CSII. This meta-analysis is aimed at assessing the
advantages of short-acting analog-based CSII over MDI in
type 1 diabetes. Randomized clinical trials (RCTs) com-
paring CSII (with analogs) and MDI for at least 12 weeks
in type 1 diabetic patients were retrieved, assessing
between-group differences in HbA1c and incidence of
hypoglycemia. A total of 11 RCTs was included in the
analysis. CSII was associated with a significant improve-
ment of HbA1c in comparison with MDI (standardized
difference in mean: -0.3 [-0.4;-0.1]%; P \ 0.001). No
significant difference was observed in the rate of severe
hypoglycemic episodes. The reduction of HbA1c with CSII
was evident in trials enrolling patients with mean age
greater than 10 years, but not in younger children. Avail-
able data justify the use of CSII for basal-bolus insulin
therapy in type 1 diabetic patients unsatisfactorily con-
trolled with MDI.
Keywords Insulin therapy  Clinical science  Humans
Introduction
Intensive (basal-bolus) insulin regimens with multiple
daily injections allow a satisfactory control of blood glu-
cose, with a limited risk of major hypoglycemia, in many
persons with type 1 diabetes. However, glycemic targets
are not reached with this approach in all patients. Contin-
uous subcutaneous insulin infusion (CSII) with external
pumps is a treatment option for patients with type 1 dia-
betes unsatisfactorily controlled with multiple daily injec-
tion regimens [1, 2].
Available evidence suggests that short-acting insulin
analogs are superior to regular human insulin (RHI) for
CSII [3, 4] as well as for traditional multiple injection
therapy in type 1 diabetes [5]. Several randomized clinical
trials, usually on small samples of patients, comparing CSII
using short-acting analogs and multiple daily injections
(MDI) have been performed, reporting either a similar
efficacy of the two approaches [6–16] or a superiority of
CSII [17, 18]. A meta-analysis on patient-level data from
three clinical trials suggests an improvement of HbA1c
with CSII (with lispro) as compared with MDI [19].
The aim of the present meta-analysis is the assessment
of differences in efficacy and hypoglycemic risk between
CSII, using short-acting analogs, and MDI, in patients with
type 1 diabetes.
Research design and methods
A meta-analysis was performed including all published
randomized clinical trials, either with a cross-over or a
parallel series design, enrolling patients with type 1 dia-
betes, with a duration of at least 12 weeks, comparing
continuous subcutaneous insulin injection (CSII) and
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multiple daily insulin injections (MDI) using short-acting
insulin analogs. Trials with a shorter duration were
excluded because they could not yield relevant information
on glycated hemoglobin, which had been chosen as the
principal outcome variable.
An extensive Medline search for ‘‘continuous subcuta-
neous insulin injection’’, ‘‘insulin pump’’, or ‘‘CSII’’ was
performed, collecting all randomized clinical trials on
humans up to July 10, 2008. The identification of relevant
abstracts, the selection of studies based on the criteria
described above, and the subsequent data extraction were
performed independently by two of the authors (Edoardo
Mannucci and Matteo Monami), and conflicts were
resolved by the third investigator (Niccolo` Marchionni).
The quality of trials was assessed using the following
parameters: adequate description of randomization, allo-
cation, blinding, and dropout procedures.
The principal outcome was the effect of CSII, as com-
pared with MDI, on HbA1c at the end of trial. Furthermore,
data on the incidence of nocturnal, severe, or any hypo-
glycemia (number of patients with at least one event) were
extracted whenever possible.
Standardized mean differences were calculated for
HbA1c and a random effect model was used for the meta-
analysis. Mantel-Haenszel odds ratio for 95% confidence
interval (MH-OR) was calculated for hypoglycemia, using
a random effect model. All analyses were performed using
Comprehensive Meta-analysis Version 2, Biostat, (Engle-
wood, NJ, USA).
Results
The trial flow is summarized in Fig. 1. The principal
characteristics of the 11 trials included in the meta-analy-
sis, which were all open-label, were reported in Tables 1
and 2. When combining results of trials, HbA1c was sig-
nificantly lower with CSII than with conventional insulin
treatment (Fig. 2). A significant reduction of HbA1c with
CSII was observed either with lispro [-0.2 (-0.4; -0.1)%,
P = 0.001] or aspart [-0.6 (-1.0; -0.2)%; P = 0.002].
Furthermore, a significant improvement of HbA1c with
CSII was detected in trials using different prandial (lispro
or aspart) and basal (glargine or NPH) insulins in MDI
(data not shown). CSII produced a significant advantage
over MDI in trials enrolling patients with a mean age
[10 years (-0.3 [-0.4; -0.2]%; P \ 0.001), but not in
studies performed on younger subjects (-0.1 [-0.5; 0.3]%;
P = 0.48).
Sixteen and 21 patients in CSII and comparator groups,
respectively, experienced at least one episode of severe
hypoglycemia; the difference between treatment arms
was not significant (MH-OR 0.80[0.39;1.63]; P = 0.53).
A formal meta-analysis on the overall incidence of hypo-
glycemia could not be performed, because this information
was not consistently reported across trials (i.e., some
studies reported number of events or incidence rates, but
not the number of patients with at least one event).
Discussion
CSII is usually proposed as a treatment option in type 1
diabetic patients who are unable to maintain a satisfactory
glycemic control with MDI. The present meta-analysis
confirms that CSII is associated with a lower HbA1c at
endpoint in comparison with MDI, supporting the utility of
this therapeutic approach. Notably, the reduction of HbA1c
Fig. 1 Trial flow diagram. RCT Randomized clinical trial, CSII
Continuous subcutaneous insulin infusion
S78 Acta Diabetol (2010) 47 (Suppl 1):S77–S81
123
with CSII was not associated with an increased risk of
severe hypoglycemia. This result is consistent with those of
a previous meta-analysis on a patient-level data from three
small trials [19], and of two larger meta-analyses which
included trials applying CSII with RHI [1, 2].
In all the trials included in the meta-analysis, MDI was
administered with a basal-bolus scheme, namely, with
short-acting insulin analogs or RHI before meals and one
or two injections of long-acting analogs or NPH insulin for
basal requirements. However, the type of prandial and
basal insulin in MDI was not consistent across trials. Short-
acting insulin analogs produce a significant reduction of
HbA1c in type 1 diabetic patients in comparison with RHI
[5]; therefore, the comparison of short-analogs as CSII with
RHI as MDI could produce a bias in favor of CSII. This
could account for the greater reduction of HbA1c reported
in a recent meta-analysis of CSII versus MDI, which
included also a large number of trials with RHI [20]. Most
available studies used NPH as basal insulin in MDI; it is
possible that long-acting analogs would have produced
better results, although the advantage of these preparations
in type 1 diabetes is controversial [5, 21]. In fact, long-
acting analogs are associated with a lower hypoglycemic
risk; however, they do not seem to produce a further
reduction of HbA1c in comparison with NPH [21].
Unfortunately, the number of trials comparing CSII with
Table 1 Characteristics of the studies included in the meta-analysis
Study
(Ref.)
Insulin
(type)
Comparator # Adminis.
(basal insulin)
Failure to Trial duration
(weeks)
Design # patients
(CSII/C)
Random Allocation Drop-out
Fox [6] ANAL ANAL/NPH 2 or 3 Insulin 26 PS 11/12 NA NA A
DiMeglio [7] LIS LIS/NPH or GL NR Insulin 26 PS 21/21 A A A
Hanaire-Broutin [8] LIS LIS/NPH 2 Insulin 16 CO 41/41 NA NA A
Hoogma [9] LIS LIS/NPH 1 or more Insulin 26 CO 256/256 NA NA A
Opipari-Arrigan [10] LIS LIS/NPH or GL NR Insulin 26 PS 6/8 NA NA A
Thomas [11] LIS LIS/GL 1 Insulin 24 PS 7/7 NA NA A
Tsui [12] LIS LIS/NPH 1 or 2 Insulin 36 PS 13/14 A A A
Wilson [13] LIS ANAL/NPH/GL NR Insulin 52 PS 9/10 A A A
DeVries [17] ASP ASP/NPH 1 or 2 Insulin 16 PS 40/39 A A A
Doyle [18] ASP ASP/GL 1 Insulin 16 PS 16/16 A A A
Bruttomesso [16] LIS LIS/GL 1 or 2 CSII 16 CO 24/15 A A A
Admin Administrations, CSII Continuous subcutaneous insulin injection, C Comparator, Random Randomization, NR Not reported, ANAL
Unspecified short-acting analogue, LIS Lispro, ASP Aspart, GL Glargine, HRI Human regular Insulin, PS Parallel series, CO Cross-over, NA Not
Adequate, A Adequate, NR Not reported
Table 2 Moderators and outcome variables in individual studies included in the meta-analysis
Study
(Ref.)
Age
(years)
Duration of
DM (years)
BMI baseline
(kg/m2)
HbA1c
baseline (%)
HbA1c endpointa
(%, CSII/C)
Insulin doses endpointa
(n, CSII/C)
Severe
hypoglycemia
(n, A/R)
Fox [6] 4 1.0 NR 7.5 7.2 ± 1.0/7.5 ± 0.7 NR 0/1
DiMeglio [7] 4 2.0 NR 9.0 8.5 ± 0.6/8.7 ± 0.7 NR 1/1
Hanaire-Broutin [8] 43 20.0 24.0 8.4 7.9 ± 0.8/8.2 ± 0.8 39 ± 10/47 ± 15 2/1
Hoogma [9] 36 15.0 24.8 8.2 7.4 ± 1.1/7.7 ± 1.4 NR NR
Opipari-Arrigan [10] 4 NR 16.5 8.1 8.4 ± 0.8/8.2 ± 0.4 NR 0/2
Thomas [11] 43 25.0 NR 8.5 7.4 ± 1.1/7.6 ± 0.7 29 ± 7/62 ± 23 2/2
Tsui [12] 36 16.0 27.0 7.9 7.4 ± 0.6/7.6 ± 0.7 NR 6/4
Wilson [13] 4 1.0 NR 8.0 8.0 ± 0.8/7.9 ± 0.8 NR 1/1
DeVries [17] 37 18.0 NR 9.3 8.4 ± 1.4/9.1 ± 1.4 54 ± 22/73 ± 31 3/6
Doyle [18] 13 6.0 NR 8.1 7.2 ± 1.0/8.1 ± 1.2 NR 2/4
Bruttomesso [16] 37 16.0 23.0 7.4 7.1 ± 0.7/7.2 ± 0.8 36 ± 8/45 ± 11 NR
Total 21.2 10.0 22.5 8.5 7.6 ± 0.9/7.9 ± 0.8 39.4 ± 13.0/56.9 ± 23.1 18/25
a Mean value between the two treatment groups. CSII Continuous subcutaneous insulin injection, C Comparator, DM Diabetes mellitus, BMI
Body mass index, NR Not reported
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MDI using analogs (glargine) as basal insulin is still too
small to produce reliable meta-analytical results. Further
research is needed to clarify this point.
It should be considered that available trials except one
[15] enrolled patients failing to MDI, who were random-
ized to continue the same unsatisfactory treatment or to
switch to CSII. Therefore, CSII, which is more expensive
than traditional injections, should be considered as a more
effective alternative only in patients who are unable to
maintain a good control with MDI, while there is no evi-
dence of an overall superiority of CSII over MDI in type 1
diabetes [22–25].
The possible mechanisms for the improvement of met-
abolic control with CSII include a more appropriate supply
of basal insulin and a easier adjustment of boluses in the
case of suboptimal blood glucose [26]. It should be con-
sidered that subgroup analysis failed to detect any relevant
improvement of metabolic control with CSII in younger
children, even if this result is controversial [27]. The rea-
sons for the apparent lack of superiority in children are
speculative; it can be hypothesized that young children are
unable to perform accurate adjustments of prandial insulin
doses, or that they are less likely to administer additional
boluses in case of moderate hyperglycemia. Notably, in
this sub-population of patients, CSII failed to produce
further benefits on metabolic control, despite its potential
for optimizing basal insulin supply.
Some of the available trials found an improvement of
health-related quality of life associated with CSII [9, 10,
17], but this result was not confirmed by other studies [11,
12, 18]. No trial reported a better quality of life with MDI
in comparison with CSII. Unfortunately, a formal meta-
analysis on the effects of CSII on quality of life is
prevented by the heterogeneity of methods used across
trials for the assessment of this parameter.
In conclusion, continuous subcutaneous infusion of
short-acting insulin analogs can improve metabolic control
in patients with type 1 diabetes who are unable to reach
glycemic targets with conventional basal-bolus regimens
with multiple daily injections.
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